The publication adds peer-reviewed evidence supporting OneRF's clinical utility, which may drive adoption among neurosurgeons. However, the small sample size and lack of comparative data limit the strength of the evidence; monitor for larger studies and any revenue disclosures in future filings.
Price Chart
Executive Summary
NeuroOne announced publication of initial clinical results for its OneRF Trigeminal Nerve Ablation System in Pain Management, showing 93.3% immediate pain freedom and all 15 patients achieving favorable outcomes at six-month follow-up. The small retrospective study supports the system's multi-contact probe design but lacks a control group and longer-term data.
Key Facts
- 14 of 15 patients (93.3%) were pain-free immediately after treatment; the 15th became pain-free within a week.
- All 15 patients achieved a good clinical outcome (BNI score I–IIIB) at a mean six-month follow-up.
- 8 patients (53.3%) were pain-free and off pain medication at last follow-up.
- No probe repositioning was required to map and treat multiple trigeminal nerve distributions.
- No off-target lesioning, ophthalmic complications, or anesthesia dolorosa were reported.
- One patient developed a cheek hematoma and transient masseter weakness, both resolved.
- The study is a small retrospective series without a direct comparison group.
Financial Impact
Not stated; no revenue or market size figures provided.
Risk Factors
- Small retrospective study (n=15) without a control group limits generalizability.
- Long-term durability of pain relief beyond six months is unknown.
- No revenue or sales guidance provided; commercial adoption may be slower than anticipated.
- Company has a market cap of $8M and may face capital constraints to fund commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391184 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | Press Release | $0.9698 | awaiting T+5 | awaiting T+5 | $0.9270 (−4.41%) |
Oct 5, 2026 27d ago | 8-K | No price | awaiting T+5 | awaiting T+5 | No price |
Oct 5, 2026 27d ago | Press Release | $1.12 $1.08 | ▼ −3.59% | ▼ −4.01% | $0.9270 (−16.86%) |
Aug 27, 2026 9w ago | 8-K | $1.98 $1.66 | ▼ −16.16% | ▼ −16.43% | $0.9270 (−53.18%) |
Aug 13, 2026 11w ago | 8-K | $1.83 $2.15 | ▲ +17.49% | ▲ +19.45% | $0.9270 (−49.34%) |
Jun 12, 2026 20w ago | 424B5 / 8-K | $3.32 $3.25 | ▲ +2.11% | ▲ +0.73% | $0.9270 (+72.08%) |
May 22, 2026 23w ago | 8-K | $3.87 $3.56 | ▲ +8.01% | ▲ +9.22% | $0.9270 (+76.05%) |
May 12, 2026 24w ago | 8-K | $4.39 $4.53 | ▲ +3.19% | ▲ +3.11% | $0.9270 (−78.88%) |
May 4, 2026 25w ago | 8-K | $4.49 $4.33 | ▼ −3.56% | ▼ −6.50% | $0.9270 (−79.35%) |
Apr 30, 2026 26w ago | 8-K | $4.70 $4.30 | ▼ −8.51% | ▼ −10.24% | $0.9270 (−80.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers